SCHEMBL5322288

SCHEMBL5322288

O=C(O)CCCc1nn(Cc2ccc(F)cc2Cl)c2cc(OC(F)(F)F)ccc12

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 7/20 0.41
FFAR1 O14842 3/20 0.41
SCN5A Q14524 2/20 0.41
CYP2C9 P11712 1/20 0.41
SLC22A12 Q96S37 2/20 0.40
TP53 P04637 3/20 0.39
CYP3A4 P08684 1/20 0.38
KCNH2 Q12809 1/20 0.38
CACNA1C Q13936 1/20 0.38
SLC16A3 O15427 1/20 0.38
SLC16A1 P53985 1/20 0.38
MCTS1 Q9ULC4 1/20 0.38
GCGR P47871 2/20 0.38
RORC P51449 2/20 0.38
PPARG P37231 1/20 0.38
MAPT P10636 1/20 0.38
PLA2G10 O15496 1/20 0.37
PLA2G2A P14555 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5317632 0.95 SLC22A12 (0.42) FFAR4FFAR1SCN5ACYP2C9SLC22A12
SCHEMBL5316023 0.92 PPARG (0.46) FFAR4FFAR1SCN5ACYP2C9SLC22A12
SCHEMBL5317096 0.91 AKR1B1 (0.43) FFAR4FFAR1CYP2C9SLC22A12CYP3A4
SCHEMBL5269646 0.90 F2RL3 (0.39) SCN5ACYP2C9TP53CYP3A4
SCHEMBL5318163 0.90 AKR1B1 (0.46) CYP2C9SLC22A12TP53CYP3A4SLC16A3
SCHEMBL5339999 0.89 F2RL3 (0.38) SCN5ACYP2C9TP53CYP3A4
SCHEMBL5343398 0.88 F2RL3 (0.38) SCN5ACYP2C9TP53CYP3A4
SCHEMBL5319971 0.88 F2RL3 (0.40) CYP2C9TP53CYP3A4SLC16A3SLC16A1
SCHEMBL5323485 0.87 FFAR4 (0.42) FFAR4FFAR1SCN5ACYP2C9SLC22A12
SCHEMBL5319646 0.87 PPARG (0.49) CYP2C9SLC22A12CYP3A4SLC16A3SLC16A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2502624-A1 Lonidamine analogues and their use in male contraception and cancer treatment THE UNIVERSITY OF KANSAS (US) 2012-09-26 EP claimed
EP-1786424-A2 LONIDAMINE ANALOGUES AND THEIR USE IN MALE CONTRACEPTION AND CANCER TREATMENT The University of Kansas (US) 2007-05-23 EP claimed
WO-2006023704-A2 LONIDAMINE ANALOGUES AND THEIR USE IN MALE CONTRACEPTION AND CANCER TREATMENT UNIVERSITY OF KANSAS (US) 2006-03-02 WO claimed